Влияние FOLFIRINOX на достижение резектабельности у пациентов с раком толстой кишки с метастазами в печень
- Авторы: Хакимов Г.А1,2, Джуманиезов Х.И1,2, Кадыров Ш.Ш1,2, Хакимова Г.Г3, Абдулхусейнова С.И3, Полужкина И.Н3
-
Учреждения:
- Ташкентский педиатрический медицинский институт, курс онкологии и детской онкологии
- Ташкентский городской филиал, Республиканский специализированный научно-практический центр онкологии и радиологии
- Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина
- Выпуск: Том 26, № 12 (2019)
- Страницы: 26-36
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/312337
- DOI: https://doi.org/10.18565/pharmateca.2019.12.26-36
- ID: 312337
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Г. А Хакимов
Ташкентский педиатрический медицинский институт, курс онкологии и детской онкологии; Ташкентский городской филиал, Республиканский специализированный научно-практический центр онкологии и радиологии
Email: hgg_doc@mail.ru
аспирант отделения химиотерапии и комбинированного лечения злокачественных опухолей 115478, Россия, Москва, Каширское ш., 23
Х. И Джуманиезов
Ташкентский педиатрический медицинский институт, курс онкологии и детской онкологии; Ташкентский городской филиал, Республиканский специализированный научно-практический центр онкологии и радиологииТашкент, Узбекистан
Ш. Ш Кадыров
Ташкентский педиатрический медицинский институт, курс онкологии и детской онкологии; Ташкентский городской филиал, Республиканский специализированный научно-практический центр онкологии и радиологииТашкент, Узбекистан
Г. Г Хакимова
Национальный медицинский исследовательский центр онкологии им. Н.Н. БлохинаМосква, Россия
С. И Абдулхусейнова
Национальный медицинский исследовательский центр онкологии им. Н.Н. БлохинаМосква, Россия
И. Н Полужкина
Национальный медицинский исследовательский центр онкологии им. Н.Н. БлохинаМосква, Россия
Список литературы
- Parkin D.M., Bray F., Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
- Беляева А.В. Мутации в гене K-ras у больных колоректальным раком: эпидемиология и клиническое значение. Дисс. канд. мед. наук. СПб., 2012.
- Andre T, Boni C., Mounedji-Boudiaf L., etal. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancel. N Engl J Med. 2004;350:2343-51. doi: 10.1056/NEJMoa032709.
- Gill S., Goldberg R.M. First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs. 2004;64:27-44.
- Hurwitz H, Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. Doi: 10.1056/ NEJMoa032691.
- Cunningham D., Humblet Y, Siena S., et al. Cetuximab monotherapy and cetuximab plus irino- tecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. Doi: 10.1056/ NEJMoa033025.
- Adam R. Chemotherapy and surgery: new perspectives on the treat- ment of unresectable liver metastases. Ann Oncol. 2003;14(Suppl. 2):13-6. Doi: 10.1093/ annonc/mdg731.
- Varol U, Cirak Y, Cakar B., et al. Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease. J B.U.ON: official journal of the Balkan Union of Oncology. 2013;18:647-52.
- Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil- leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-14. Doi: 10.1200/ JCO.2004.11.037.
- De Gramont A., Figer A., Seymour M., et al. leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
- Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30. doi: 10.1200/JCO.2004.09.046.
- Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first- line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-76. Doi: 10.1200/ JCO.2006.09.0928.
- Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Metaanalysis Group In Cancer. J Clin Oncol. 1998;16:301-8. Doi: 10.1200/ JCO.1998.16.1.301.
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer MetaAnalysis Project. J Clin Oncol. 1992;10:896-903. doi: 10.1200/JCO.1992.10.6.896.
- Piedbois P, Michiels S. Meta-Analysis Group in Cancer. Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated metaanalysis based on 2,751 patients. Proc Am Soc Clin Oncol. 2003;22:294.
- Kohne C.H., Van Cutsem E., Wils J.A., et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol. 2003;22:254.
- Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-47. Doi: 10.1200/ JCO.2000.18.1.136.
- Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2002;21:129a.
- Tournigand C., Andre T., Achille E., et al. FOLFIRI Followed by FOL- FOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. J Clin Oncol. 2004;22:229-37.
- Buyse M., Thirion P, Carlson R.W., et al. Relation between tumor response to first-line chemo- therapy and survival in advanced colorectal cancer: A metaanalysis. Lancet. 2000;356:373-8. DOI: 10.1016/ S0140-6736(00)02528-9.
- Giacchetti S., Itzhaki M., Gruia G., et al. Long- term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxali- platin and surgery. Ann Oncol. 1999;10:663-69. doi: 10.1023/a:1008347829017.
- Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347-53. doi: 10.1007/s10434-001-0347-3.
- Bismuth H., Adam R., Levi F, et al. Resection of nonresectable liver metastas.s from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-20.
- Folprecht G., Grothey A., Alberts S., et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311-19. doi: 10.1093/annonc/mdi246.
- Alberts S.R., Donohue J.H., Mahoney M.R., et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol. 2003;22:263.
- Pozzo C., Basso M., Cassano A., et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-39. doi: 10.1093/annonc/mdh217.
- de la Camara J., Rodriguez J., Rotellar F, et al. Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3593).
- Quenet F, Nordlinger B., Rivoire M., et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3613).
- Roth A.D., Seium Y, Ruhstaller T., et al. Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5FU/ leucovorin (OCFL) in metastatic colorectal cancer (MCRC): a phase I-II study. Proc Am Soc Clin Oncol. 2002;21:143a.
- Scheele J., Stang R., Altendorf Hofmann A., Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71. doi: 10.1007/bf00316981.
- Fong Y, Fortner J., Sun R.L., et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-18. doi: 10.1097/00000658-199909000-00004.
- Nordlinger B., Guiguet M., Vaillant J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-62.
- Figueras J., Valls C., Rafecas A., et al. Resection rate and effect of post- operative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88:980-85. doi: 10.1046/j.0007-1323.2001.01821.x.
- Tabernero J., Van Cutsem E., Sastre J., et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol. 2004;23 (Abstr. 3512).
- Folprecht G, Lutz M., Schoffski P, et al. Cetuximab/ irinotecan/ high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Proc Gastrointest Canc Symp. (ASCO/AGA/ASTRO/SSO) 2004;1:(Abstr. 283).
- Saltz L.B., Meropol N.J., Loehrer PJ.Sr., et al. Phase H trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-208. doi: 10.1200/JCO.2004.10.182.
- Lenz H.-J, Mayer R.J., Gold PJ., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3510).
- Saltz L., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol. 2001;20:3a.
- Rougier P, Raoul J.L., Van Laethem J.L., et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol. 2004;23:(Abstr. 3513).
- Lutz M.P, Schoffski P, Folprecht G., et al. A phase I/ II study of cetuximab (C225) plus irinotecan (CPT-11) and 24 h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol. 2002;13:73.
- Rosenberg A.H., Loehrer P.J., Needle M., et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am SocClin Oncol. 2002;21:135a.
- Scappaticci F., Fehrenbacher L., Cartwright T., et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. Proc Gastrointest Canc Symp. (ASCO/ AGA/ASTRO/SSO) 2004;1:(Abstr. 235).
- Chaix M., Vincent J., Lorgis V., Ghiringhelli F. FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. Oncol. 2014;87:148-58. doi: 10.1159/000361031.
- Adam R., Pascal G., Castaing D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases. Ann. Surg. 2004;240:1052-61. doi: 10.1097/01. sla.0000145964.08365.01.
- Sanoff H., Sargent D., Campbell M., et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N 9741. JClin Oncol. 2008;26:5721-27. doi: 10.1200/JCO.2008.17.7147.
- Choti M.A. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66. doi: 10.1097/00000658-200206000-00002.
- Nordlinger B., Sorbye H., Glimelius B., et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol. 2012;30(Abstr. 3508).
- Adam R., Frilling A., Elias D., et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010;97:366-76. doi: 10.1002/bjs.6889.
- Abdalla E.K., Vauthey J.N. Colorectal metastases: resect or ablate? Ann Surg Oncol. 2006;13:602-3. doi: 10.1245/ASO.2006.09.920.
- Ferrero A. Postoperative liver dysfunction and future remnant liver: Where is the limit? Results of a prospective study. World J Surg. 2007;31:1643-51. doi: 10.1007/s00268-007-9123-2.
- Oki E., Emi Y, Yamanaka T, et al. Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial). Br J Cancer 2019. doi: 10.1038/s41416-019-0518-2.
- Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008. 26:1830-35. doi: 10.1200/JCO.2007.13.7679.
Дополнительные файлы
![](/img/style/loading.gif)